Hongmo Biologics 2 '- FL (2' - fucosylactose) was approved by the National Health Commission in October this year, becoming one of the first Chinese local HMO enterprises to be approved. It has been dubbed by many media as a "Chinese dark horse that has solved the bottleneck problem of Western technology.".

In fact, as early as 2022, Hongmu Biotechnology began to expand its overseas market and conducted a self GRAS scientific evaluation in accordance with the US FDA GRAS guidelines in June this year, which was approved by experts

As a newly emerging raw material enterprise in China, Hongmo Biotechnology has won multiple "China's Local First" awards, making a sudden rise and gaining great attention for its strength! The core product HMO produced has won multiple "firsts", with special honors and unstoppable momentum.

In January 2023, Hongmo Biotechnology became the first Chinese HMO raw material enterprise to pass the safety assessment of the Ministry of Agriculture and Rural Affairs;

In June 2023, obtained the US FDA's self GRAS market access permit;

In the same month, the scientific consensus on breast milk oligosaccharides (HMOs) was officially published in the Chinese Journal of Food Science, and Hongmo Biotechnology became the first Chinese HMO raw material enterprise to participate in this authoritative publication;

In October 2023, Hongmo Biological HMO was approved by the National Health Commission, becoming the first and only local Chinese enterprise among the first batch of approved enterprises.

As a leader in local HMO in China, Hongmo Biotechnology possesses strong development potential and also shoulders important responsibilities and responsibilities in leading local enterprise innovation.

After scientific verification, the HMO products produced by Hongmo Biotechnology have a completely identical structure to the HMO extracted from Chinese mothers' breast milk. HMO (breast milk oligosaccharides) has significant effects in maintaining intestinal health, improving the immune system, and enhancing cognitive abilities.

In terms of maintaining intestinal health, HMO can repair intestinal barriers, improve gut microbiota microbiota, and alleviate intestinal diseases;

At the level of improving the immune system, HMO can promote immune system maturation, resist pathogen invasion, and alleviate allergic reactions;

In terms of enhancing cognitive abilities, HMO has achieved remarkable results in promoting brain development and improving learning and memory abilities.

Clinical studies have shown that the addition of HMO can increase the proportion of bifidobacteria in the intestines of infants and young children, reduce the probability of lower respiratory tract infections and otitis media, and reduce the use of antipyretics and antibiotics. For adults, HMO also has the effect of improving symptoms of irritable bowel syndrome and ulcerative colitis.

Hongmo Biological 2 '- FL has obtained dual certifications from the US Self GRAS and the Chinese Health Commission, which is a new milestone in the research and application of HMO. In the future, it will continue to deepen innovative research on active ingredients such as oligosaccharides in breast milk, actively expand the boundaries of scientific research categories, and actively layout in other health fields, achieving an organic combination of scientific research and industrialization of achievements.

Hongmo Biology is willing to carry the mission of local innovation, continue to promote the vigorous development of local biosynthesis technology, and help China become the flag benchmark of the fourth industrial wave.